University of California

SmartRent Names Daryl Stemm as Chief Financial Officer

Retrieved on: 
Wednesday, November 15, 2023
Software, Mobile, Wireless, Internet, Hardware, Consumer Electronics, IOT (Internet of Things), Apps, Applications, Technology, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Retail, Home Goods, Initial public offering, Accounting, NYSE, Risk management, Business economics, CFO, Treasury, Best Western, Adjustment, University, Invitation Homes, SMRT, University of California, Economics, Management

SmartRent , Inc. (NYSE: SMRT), the leading provider of smart home and property operations solutions for the rental housing industry, today announced the appointment of Daryl Stemm as its Chief Financial Officer.

Key Points: 
  • SmartRent , Inc. (NYSE: SMRT), the leading provider of smart home and property operations solutions for the rental housing industry, today announced the appointment of Daryl Stemm as its Chief Financial Officer.
  • Prior to joining SmartRent, he held senior finance positions with Best Western Hotels and Invitation Homes (NYSE: INVH), and served as CFO at Home Director, Inc., and Catalyst Semiconductor, Inc.
  • “We are pleased to appoint Daryl as CFO for SmartRent,” said SmartRent CEO Lucas Haldeman.
  • “He has been an integral part of our team, helping SmartRent scale and grow to become the leading provider in our space.

REPLY: Second Edition of “Cloud in Financial Services” Report Unveils New Insights Into the Cloud Adoption Landscape for Financial Institutions in the Europe and the UK

Retrieved on: 
Wednesday, November 15, 2023
Technology, Consulting, Other Technology, Professional Services, Data Analytics, IOT (Internet of Things), Data Management, Other Professional Services, Artificial Intelligence, Cloud, European Banking Federation, Technology management, Research, Imperial College Business School, EXM, Insurance, Multimedia, Machine learning, Financial services, University, Internet, Cloud computing, Insurance Europe, University of California, AI, STAR, Management, Network equipment provider

This report offers a comprehensive view of the dynamic cloud adoption landscape in the financial services sector, focusing on key aspects such as cloud strategy, governance, regulation, and data.

Key Points: 
  • This report offers a comprehensive view of the dynamic cloud adoption landscape in the financial services sector, focusing on key aspects such as cloud strategy, governance, regulation, and data.
  • View the full release here: https://www.businesswire.com/news/home/20231115080335/en/
    The second edition of the “Cloud in Financial Services” report re-examines the research conducted by Reply with financial institution, and addresses the unique challenges facing financial institutions in the EU, Switzerland, and UK.
  • Significantly, 34% of respondents pinpoint these concerns as the primary challenge to embracing cloud solutions in their financial institutions.
  • This data offers an insightful comparison between the anticipated and actual implementation of machine learning empowered by the cloud.

KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Syringe, Real, Attack, Asthma, Lung compliance, Patient, Division, American College, Internal medicine, Hereditary angioedema, Anxiety, KALV, HAE, University, Pain, University of California, Freie Berliner Kunstausstellung, ACAAI, Rheumatology, Immunology

“We continue to learn from people living with HAE that currently available parenteral on-demand treatments are simply not meeting their needs,” said Andrew Crockett, Chief Executive Officer of KalVista.

Key Points: 
  • “We continue to learn from people living with HAE that currently available parenteral on-demand treatments are simply not meeting their needs,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • “Whether this is related to always carrying their syringes or vials, challenges in preparing and administering injectable or infused treatments outside the home, or anxiety related to potential injection-site reactions and pain, patients struggle to follow treatment guidelines.
  • This can lead to non-compliance and preference for long-term prophylaxis, even in cases where on-demand treatments would otherwise suffice.
  • We also note that despite the use of long-term prophylaxis, HAE patients require HAE-related home health visits and seek ER treatment more often than would be expected.

Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform

Retrieved on: 
Tuesday, December 12, 2023
Research, Immune system, Engineering, Therapy, Bone marrow, Kyoto University, Biotechnology, Patient, Cell, Regenerative medicine, Autoimmune disease, IPSC, University, University of California, Coronavirus Scientific Advisory Board, Global Partnership for Education, FTI, Pharmaceutical industry, Vaccine, Ninja, Katana

SAN FRANCISCO and KYOTO, Japan, Dec. 12, 2023 /PRNewswire/ -- Shinobi Therapeutics (Shinobi), the biotechnology company developing a new class of immune evasive iPS-T cell therapies, today announced that it has closed a $51 million Series A financing. The oversubscribed round was led by EQT Life Sciences, F-Prime Capital and Eight Roads Ventures Japan, with participation from Astellas Venture Management, Fast Track Initiative (FTI), JIC Venture Growth Investments, and D3 LLC. Shinobi will use the funds to advance its 'Katana' iPS-T cell therapy platform and progress its first program to treat GPC3+ solid tumor cancers toward the clinic.

Key Points: 
  • Shinobi will use the funds to advance its 'Katana' iPS-T cell therapy platform and progress its first program to treat GPC3+ solid tumor cancers toward the clinic.
  • "Having led several cell therapy programs at other global companies, I've never encountered a technology platform that is capable of advancing the field as dramatically as this."
  • "Shinobi stands alone in the growing cell therapy field by engineering the most comprehensive immune evasion technology directly into its cell products," said Robert Weisskoff, Ph.D, Partner at F-Prime Capital.
  • "Shinobi's hypoimmune technology opens the door to a broader pipeline of off-the-shelf cell therapies far beyond T cells and oncology.

Scholars citing racial effects of university funding cuts win Grawemeyer education prize

Retrieved on: 
Thursday, December 7, 2023
Investment, Psychology, Student, Multimedia, Religion, University of Chicago Press, Nielsen, Music, COVID-19, University, School, Grawemeyer Award, University of California, Public university, UC, Tutoring, Education

Two University of California sociologists exploring that question are cowinners of the 2024 University of Louisville Grawemeyer Award in Education for their ideas in "Broke: The Racial Consequences of Underfunding Public Universities."

Key Points: 
  • Two University of California sociologists exploring that question are cowinners of the 2024 University of Louisville Grawemeyer Award in Education for their ideas in "Broke: The Racial Consequences of Underfunding Public Universities."
  • In the work, Laura Hamilton and Kelly Nielsen argue that decades of cuts in public funding for public universities have eroded schools' abilities to deliver a quality education to racially and economically marginalized students.
  • For years, public universities operated mainly with government funds, which have been tapering off since the 1980s.
  • Hamilton and Nielsen make a compelling case for rethinking the way we fund public universities, said education award director Jeff Valentine.

Firegang Dental Marketing Welcomes Johnny Miller as Their New Senior Director of Practice Growth

Retrieved on: 
Tuesday, November 28, 2023
Constellation, NBC, Citibank, Dentist, Pepsi, Patient, Marketing, University, Advertising, Data collection, Social media, SEO, Communication, L'Oréal, Growth, University of California, Health, Dentistry, Sales, Journalism, Nestlé

SPOKANE, Wash., Nov. 28, 2023 /PRNewswire/ -- Firegang Dental Marketing , an industry-leading dental marketing company, announces the addition of Johnny Miller as their new Senior Director of Practice Growth.

Key Points: 
  • SPOKANE, Wash., Nov. 28, 2023 /PRNewswire/ -- Firegang Dental Marketing , an industry-leading dental marketing company, announces the addition of Johnny Miller as their new Senior Director of Practice Growth.
  • "Our goal is simple: to drive profitable new patients to our dental clients," says Ryan Menacho, Director of Marketing for Firegang Dental Marketing.
  • With over 20 years of global expertise in channel sales, marketing, and interactive marketing, Johnny has successfully led projects worldwide.
  • Firegang Dental Marketing offers a wide range of marketing services for dentists , including website development , SEO, social media advertising, call coaching, Google Ads, and more.

Zymo Research Announces Sponsorship of the Inaugural Microbes in Wastewater Symposium

Retrieved on: 
Tuesday, November 21, 2023
NSF, Research, Engineering, Microbiology, Waterborne diseases, Collection, Marketing, AMR, University, Infection, NGS, University of California, Environmental health

IRVINE, Calif., Nov. 21, 2023 /PRNewswire/ -- Zymo Research Corporation proudly announced its sponsorship of the upcoming "Microbes in Wastewater: Molecular Approaches in Pathogen and AMR Surveillance" symposium, scheduled for January 18th -19th, 2024, in Laguna Beach, California.

Key Points: 
  • IRVINE, Calif., Nov. 21, 2023 /PRNewswire/ -- Zymo Research Corporation proudly announced its sponsorship of the upcoming "Microbes in Wastewater: Molecular Approaches in Pathogen and AMR Surveillance" symposium, scheduled for January 18th -19th, 2024, in Laguna Beach, California.
  • The aim is to foster conversations on technologies and methods for the standardization of wastewater testing and surveillance.
  • Zymo Research's sponsorship emphasizes its dedication to advancing scientific knowledge in wastewater research while stressing the importance of public and environmental health.
  • Attendees are invited to explore Zymo Research's booth to learn about cutting-edge solutions enhancing molecular approaches in wastewater research.

Announcing 2023 Infrastructure Grants to Support Clinical Trials

Retrieved on: 
Tuesday, November 21, 2023
Clinical trial, University of California, Child, Research, Hope, Nursing, Hospital, St. Baldrick's Foundation

LOS ANGELES, Nov. 21, 2023 /PRNewswire/ -- The St. Baldrick's Foundation , the largest charity funder of childhood cancer research grants , is thrilled to announce $1.1 million in new grants to bolster pediatric cancer clinical trial enrollment.

Key Points: 
  • LOS ANGELES, Nov. 21, 2023 /PRNewswire/ -- The St. Baldrick's Foundation , the largest charity funder of childhood cancer research grants , is thrilled to announce $1.1 million in new grants to bolster pediatric cancer clinical trial enrollment.
  • Clinical trials play a crucial role in the fight against childhood cancer.
  • The unsung heroes who help make clinical trials happen for kids are the dedicated clinical research associates, nurses, and support staff.
  • These grants would not be possible without the support of St. Baldrick's volunteers, supporters and donors.

BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia

Retrieved on: 
Friday, November 17, 2023
Biomarker, Safety, Brainstorm, CSF, Cedars-Sinai Medical Center, Research, California Pacific Medical Center, Event, University, MD, Survival, Neuroinflammation, Mayo Clinic, University of California, Neuroprotection, Cerebrospinal fluid, HIV disease progression rates, Hospital, Medical imaging, ALS

NEW YORK, Nov. 17, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE. The presentation will feature new analyses from the NurOwn placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that highlight the biological effect of NurOwn through CSF biomarker data. The presentation, titled, "NurOwn for ALS: Biomarker exploration of NurOwn multimodal mechanism of action on neuroinflammation, neuroprotection and neurodegeneration" will be presented by Bob Dagher, MD, Executive Vice President and Chief Development Officer at BrainStorm.

Key Points: 
  • Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes
    NEW YORK, Nov. 17, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE.
  • The presentation will feature new analyses from the NurOwn placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that highlight the biological effect of NurOwn through CSF biomarker data.
  • The presentation, titled, "NurOwn for ALS: Biomarker exploration of NurOwn multimodal mechanism of action on neuroinflammation, neuroprotection and neurodegeneration" will be presented by Bob Dagher, MD, Executive Vice President and Chief Development Officer at BrainStorm.
  • A copy of the presentation will be available on the Events & Presentation page of Brainstorm's corporate website following the presentation.

Lupus Foundation of America Awards Scientists for Notable Contributions to Lupus Research

Retrieved on: 
Sunday, November 12, 2023
Associate, Research, Jean, Lupus Foundation of America, Epidemiology, Disease, Cumming School of Medicine, Patient, Faculty, University of Calgary, Lupus, Division, Translational research, Science, Autoimmune disease, FRCPC, Weldon Humble, University, SLE, Lupus nephritis, MPH, Diagnosis, CDC, San Francisco Bay Area, LFA, Biomarker, University of California, Biology, Forestry, Nursing, Pharmaceutical industry, Rheumatology, MD

WASHINGTON, Nov. 12, 2023 /PRNewswire/ -- The Lupus Foundation of America (LFA) is pleased to recognize two leading lupus researchers at the 2023 Evelyn V. Hess Reception.

Key Points: 
  • WASHINGTON, Nov. 12, 2023 /PRNewswire/ -- The Lupus Foundation of America (LFA) is pleased to recognize two leading lupus researchers at the 2023 Evelyn V. Hess Reception.
  • She is the current chair of LuCIN, a network of academic institutions collaborating in the conduct of lupus clinical trials.
  • "As a practicing rheumatologist, I am passionate about lupus research because I see firsthand how this disease disproportionately impacts historically vulnerable communities.
  • Dr. Choi was funded by several career development awards including the Lupus Foundation of America Gary S. Gilkeson Career Development Award, during which she was supervised by her mentor, Dr. Karen Costenbader.